Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Noopept vs P21
An educational, source-based comparison of Noopept and P21 — how each peptide works, what it's researched for, and what to know before going deeper.
Dipeptide-derived nootropic researched for memory and neuroprotection.
A synthetic dipeptide (N-phenylacetyl-L-prolylglycine ethyl ester) derived from the endogenous nootropic cycloprolylglycine. Research suggests it potentiates AMPA receptor activity, increases BDNF and NGF expression, and provides antioxidant protection in neuronal tissue.
- Memory consolidation and retrieval
- Neuroprotection in ischemic injury
- Anxiety and emotional modulation
- Age-related cognitive decline
- • Approved in Russia; not FDA-approved in the US.
- • Generally well tolerated with few reported side effects.
A synthetic peptide derived from cerebrolysin. Research suggests it promotes synaptic plasticity by enhancing BDNF expression and inhibiting prolyl endopeptidase, an enzyme involved in neurodegenerative processes.
- Synaptic plasticity and memory
- Neuroprotection in Alzheimer's models
- Cognitive recovery after brain injury
- • Experimental; limited human data available.
- • Not FDA-approved.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Two cited studies; independent replication needed.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Noopept | Noopept neuroprotective effects in cerebral ischemia | Bulletin of Experimental Biology and Medicine | 2009 | Demonstrated protective effects against glutamate neurotoxicity in vitro. |
| Noopept | Noopept in mild cognitive impairment | Advances in Gerontology | 2012 | Improved cognitive scores in elderly patients with mild cognitive disorders. |
| P21 | P21 promotes synaptic plasticity in aged rodents | Neuroscience Letters | 2015 | Enhanced dendritic spine density and BDNF expression in hippocampal tissue. |
Side-effect & safety grid
- Approved in Russia; not FDA-approved in the US.
- Generally well tolerated with few reported side effects.
- Experimental; limited human data available.
- Not FDA-approved.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Noopept vs P21 — Key differences
- Class: Noopept is classified as Nootropic · Neuroprotection, while P21 is Nootropic · Neuroprotection.
- Primary research focus: Noopept — memory consolidation and retrieval; P21 — synaptic plasticity and memory.
- Tag: Cognition vs Cognition · Neuroprotection.